The use of surrogate endpoints in regulating medicines for cardio-renal disease: opinions of stakeholders.
There is discussion whether medicines can be authorized on the market based on evidence from surrogate endpoints. We assessed opinions of different stakeholders on this topic.We conducted an online questionnaire that targeted various stakeholder groups (regulatory agencies, pharmaceutical industry,...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4182561?pdf=render |